Mathematical and Computational Sciences SIG

Dr. Gilbert Koch is an interdisciplinary scientist with mathematical background. Currently he works as Senior Research Fellow in the Pediatric Pharmacology and Pharmacometrics Group at the University Children’s Hospital in Basel, Switzerland. Additionally, he holds an Adjunct Assistant Professor position at the University of New York at Buffalo, NY, USA.

Dr. Koch’s interests are pediatric and rare disease related optimal drug dosing questions, modeling of drug-drug interaction at various levels, advanced mathematical modeling techniques such as delay differential equations, mathematical rigorous optimization approaches to compute optimal dosing regimens, target-mediated drug disposition models with more drugs and more targets, and finally development of decision support tools to assist clinicians in daily practice. His PhD was sponsored by Nycomed (now Takeda) and his PostDoc at the University at Buffalo, NY, was funded by Fonds National de la Recherche Luxembourg, Marie-Curie Action.

Dr. Craig Thalhauser is a mathematician and currently holds the position of a Director, Quantitative Systems Pharmacology (QSP) at Genmab. He received his Ph.D. in mathematics from Arizona State University after an M.S. in Cellular and Molecular Physiology from Tufts University. His work since the start of his postdoctoral fellowship has been to apply mathematical models to questions of biology to generate new hypotheses about the dynamics of a process or disease.

Prior to joining Genmab, Dr. Thalhauser was a Research Fellow in the Quantitative Clinical Pharmacology group at Bristol-Myers Squibb, where he led QSP efforts in autoimmune disease drug development. Prior to BMS, he was a mathematical modeler at Immunetrics, Inc, a biosimulation CRO specializing in QSP model development in inflammation.

Peiying Zuo is a Director in the Pharmacometrics US group at Astellas Pharma. She received her Ph.D. in applied mathematics with a concentration in molecular and cellular biophysics from the University of North Carolina in Chapel Hill.  After 8 years in the clinical pharmacology group at GSK and 1.5 years at PAREXEL, Peiying joined Astellas in 2016, supporting application of model-based drug development (MIDD) primarily in oncology and immune-oncology. With experience across numerous therapeutic areas and in all drug development phases, her areas of expertise include concentration-QT analyses, modeling in viral dynamics and immuno-oncology, population PK in pediatrics, and more recently PKPD modeling for antibody-drug conjugates (ADC). Outside her work, Peiying is currently involved in the Innovation & Quality (IQ) Consortiums for ADCs and COVID-19. She is also an enthusiastic member and officer in the Astellas Toastmasters club.